These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 25712454)
1. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454 [TBL] [Abstract][Full Text] [Related]
2. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165 [TBL] [Abstract][Full Text] [Related]
5. Ibrutinib for the treatment of mantle cell lymphoma. Shah N; Hutchinson C; Rule S Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606 [TBL] [Abstract][Full Text] [Related]
6. [Ibrutinib: A new drug of B-cell malignancies]. Thieblemont C Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882 [TBL] [Abstract][Full Text] [Related]
7. Novel therapies for relapsed/refractory mantle cell lymphoma. Arora PC; Portell CA Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660 [TBL] [Abstract][Full Text] [Related]
9. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811 [TBL] [Abstract][Full Text] [Related]
10. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309 [TBL] [Abstract][Full Text] [Related]
11. Postibrutinib outcomes in patients with mantle cell lymphoma. Martin P; Maddocks K; Leonard JP; Ruan J; Goy A; Wagner-Johnston N; Rule S; Advani R; Iberri D; Phillips T; Spurgeon S; Kozin E; Noto K; Chen Z; Jurczak W; Auer R; Chmielowska E; Stilgenbauer S; Bloehdorn J; Portell C; Williams ME; Dreyling M; Barr PM; Chen-Kiang S; DiLiberto M; Furman RR; Blum KA Blood; 2016 Mar; 127(12):1559-63. PubMed ID: 26764355 [TBL] [Abstract][Full Text] [Related]
12. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351 [No Abstract] [Full Text] [Related]
13. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400 [TBL] [Abstract][Full Text] [Related]
14. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928 [TBL] [Abstract][Full Text] [Related]
15. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106 [TBL] [Abstract][Full Text] [Related]
16. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709 [TBL] [Abstract][Full Text] [Related]
17. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718 [TBL] [Abstract][Full Text] [Related]
18. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. Rai S; Tanizawa Y; Cai Z; Huang YJ; Taipale K; Tajimi M Adv Ther; 2022 Oct; 39(10):4792-4807. PubMed ID: 35984628 [TBL] [Abstract][Full Text] [Related]
19. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755 [TBL] [Abstract][Full Text] [Related]
20. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]